At Amalgam, we’ve never been afraid to be the first. Our leadership team has more than 15 years of experience developing, clearing, and deploying groundbreaking patient support programs and SaMD Digital Therapeutics that transform care delivery.
Our mission is to empower patients and providers to make the best healthcare decisions possible.
An exceptional blend of art, science, and technology
We create and distribute digital products that are often regulated, including digital medicine, patient identification, clinical decision support, clinical trial recruiting, and more.
Our modular platform enables rapid solution creation and is directly integrated in the EHR workflow - allowing for rapid scale across health systems and around the world.
Today, Amalgam's algorithms and applications support nearly 10 million patients across 4 continents and have helped providers make over 50 million decisions.
Meet our Executive Team and our Board of directors.
Chief Executive Officer
Dr. Suzanne Clough, MD
Chief Medical Officer
Chief Technology Officer
Chief Operating Officer and Chief Financial Officer
Chief Data Scientist and Head of AI
Jane Buus Laursen
Prior to founding Amalgam Rx, Mr. Sysko was the Co-Founder, CEO, and Chairman of WellDoc. The company helped pioneer the mobile health (“mHealth”) industry with one of the earliest FDA cleared, clinically-validated (through multiple randomized controlled trials), prescribed and reimbursed digital health products. The American Diabetes Association has listed WellDoc’s product, BlueStar, as the first and only Mobile Prescription Therapy. WellDoc has been recognized by Forbes as “One of America’s Most Promising Companies,” by the NASDAQ as “One of the Next Great Consumer Brands,” and by SmartCEO as a “Future 50 Fastest Growing Company.” Mr. Sysko has extensive background in helping to launch and develop start-up companies.
He was previously the senior vice president and director of marketing and business development for The Credo Group, one of the leading direct-to-consumer marketers of life and health insurance products on the Web. Prior to The Credo Group, he served in management positions within financial services companies such as Chase, Bank of America, and Conseco.
Mr. Bergstrom has been on the forefront of digital health for more than a decade. Recently serving as Partner and Head of Digital Therapy at Boston Consulting Group (BCG) where he helped the world’s leading life sciences companies design their digital health strategy. Prior to BCG, Chris was Chief Commercial Officer at WellDoc where he launched the world’s first digital therapy. He has a passion for championing the use of digital to decentralize healthcare and disrupt business models. As a recognized thought-leader, Chris is a frequent speaker and a former advisor to institutions such as ADA, FDA, & NIH. He also held executive roles at Roche, Becton Dickinson, P&G, and earned a BS from the IU Kelley School of Business and an MBA from Columbia University.
Prior to founding Amalgam Rx, Dr. Clough was the Co-Founder and Chief Medical Officer of WellDoc. Under Dr. Clough’s guidance, WellDoc developed the ﬁrst clinically-validated, FDA-cleared, prescribed, and reimbursed software application for type 2 diabetes management. She is considered an SME in digital health behavioral and clinical frameworks and has extensive product development experience across the chronic disease domain. Prior to founding WellDoc, Dr. Clough, an internist, and endocrinologist by training was the founder and Medical Director at the Center for Weight Management and Wellness at the University of Maryland’s Medical Center (UMMC). While at UMMC, she was responsible for developing and managing the medical management protocols for the Center for Weight Management and Wellness, developing public service campaigns aimed at ﬁghting obesity, providing clinical care for patients with general endocrinology issues and diabetes, and participating in the medical education of students, residents, and fellows.
Mr. Prasad is an experienced software architect and developer. Prior to founding Amalgam Rx, he was one of the initial technical hires at WellDoc where he was responsible for developing the BlueStar mobile and web platforms. Prior to WellDoc, Mr. Prasad was a Principal Investigator in Temasek Polytechnic’s Technology Research and Development unit, located in Singapore. During his tenure at Temasek Polytechnic, he led many software projects in collaboration with companies like Motorola, Philips, Siemens, and other local companies in Singapore.
Ms. Main joined Amalgam Rx from Centers for Medicare and Medicaid Services (CMS) where she has served as COO, responsible for a wide range of functions, including financial management, information technology, acquisition, human capital, facilities, strategic planning, and enterprise risk management. Prior to that, she held senior executive titles, including that of CFO, in five different public and private organizations over the span of her 25+ year career.
Ms. Main served as CFO for the Troubled Assets Relief Program (TARP) at the United States Department of Treasury. She led the design, development, and implementation of all areas of financial management for the $700 billion program, which was established to restore stability after the financial crisis of 2008. Previously, Ms. Main served in the roles of both COO and CFO at Millstein & Co., a boutique investment bank, between 2012 and 2016. Responsible for creating and managing all financial, human resources, and technology operations and systems to support the financial advisory and investment business, Ms. Main also served on the Board of Directors of DLT Solutions, a Millstein portfolio company. Millstein & Co. was acquired by Guggenheim Securities in 2018. Ms. Main also has startup experience as a founder of BusinessDataSource, which was later acquired by LoanChannel.
Ms. Main holds a master’s degree in public policy from Harvard University and a bachelor’s degree from Cornell University in history.
Bharath Sudharsan is our Chief Data Scientist and Head of AI. He brings with him over a decade of experience applying AI/Machine Learning methods to complex problems, institutionalizing data-driven approaches, building health data science systems and platforms at scale, and leading cross-functional teams worldwide. He is a visionary with several patents in digital health and AI and has been instrumental in successfully launching several high-impact healthcare products across markets.
A data scientist by training, he started his career at WellDoc, driving innovation around systems for chronic health domains. He then led the AI team at Quanttus for wrist-worn BP sensing algorithms. His passion for behavior change led to his own startup Geetha, where he developed a psychology AI platform. As a Digital Health AI expert, he has helped several fortune 100 healthcare companies reinvent their data science strategy and realize value using AI. He recently served as the VP of Data Science and Innovation at ArmadaHealth (part of $3B SiriusPoint), a patient navigation platform. He was trained at Stanford & MIT (Data Science), U.Mass (Engg.), and U. of Alberta (AI).
Jeff has over 30 years of experience in the financial service industry and currently is the Chief Operating Officer at Mercury Financial, a national consumer lender. He previously served at JPMorgan Chase for nearly 20 years as Managing Director in a variety of roles. Jeff started his career with MBNA where he held the position of First Vice President.
Jane is currently Corporate Vice President and head of Integrations & Strategic Alliances, Corporate Development at Novo Nordisk. Jane’s experience as a pharmaceutical business development professional includes clinical stage and on-market product related deal making, acquisitions, licensing, and collaboration deals. She holds a PhD in medicinal chemistry with extensive knowledge of lead generation methodology and experience in project leadership and CRO management.
Sonny founded and runs Alabaster, a family office that invests in founders building companies with radical solutions, usually involving "deeptech" that will have a positive, planet-level impact.
Sonny currently serves as CEO for Arevo (an Alabaster portfolio company), an advanced manufacturing technology company that automates the design and production of large continuous carbon fiber thermoplastic composite parts. Demonstration products include: www.superstrata.bike, www.scotsman.me, www.mishima.studio
Sonny previously co-founded companies such as:
- Impact Biosystems (2019)- novel muscle fitness sensing devices
- Elemental Machines (2014) - hardware and software for lab operations monitoring and analytics
- Misfit (2011) - fashion-driven wearables and smart home devices (acquired by Fossil for $260m, served as President and CTO for Fossil Group afterward)
- AgaMatrix (2001) - blood glucose monitoring devices and digital health tech for diabetes
Sonny is a mathematician by training and was a Ph.D. candidate at MIT prior to working in the software industry.